Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 7/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | SCD5 | Q86SK9 | 4/20 | 0.38 |
| ▸ | SCD | O00767 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22232765 | 1.00 | RIPK1 (0.43) | RIPK1HSD11B1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL26089736 | 0.86 | RIPK1 (0.41) | RIPK1HSD11B1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL22210929 | 0.86 | POLB (0.45) | RIPK1CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL18921253 | 0.85 | TRPA1 (0.40) | RIPK1ALDH1A1 | |
| SCHEMBL20580089 | 0.85 | RIPK1 (0.48) | RIPK1ALDH1A1 | |
| SCHEMBL20580075 | 0.85 | HSD11B1 (0.45) | RIPK1HSD11B1ALDH1A1 | |
| SCHEMBL18921354 | 0.83 | RIPK1 (0.39) | RIPK1HSD11B1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL22444793 | 0.83 | RIPK1 (0.49) | RIPK1SCD5ALDH1A1 | |
| SCHEMBL29730037 | 0.83 | RIPK1 (0.49) | RIPK1SCD5ALDH1A1 | |
| SCHEMBL26087673 | 0.83 | RIPK1 (0.49) | RIPK1SCD5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037330-B2 | Heteroaryl derivative compounds, and uses thereof | VORONOI INC. (KR) | 2024-07-16 | — | — | US | disclosed |
| US-20240166640-A1 | HETEROARYL DERIVATIVE COMPOUNDS, AND USES THEREOF | VORONOI INC. (KR) | 2024-05-23 | — | — | US | disclosed |
| EP-4342895-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | Voronoi Inc. (KR) | 2024-03-27 | — | — | EP | disclosed |
| US-20240025888-A1 | HETEROARYL DERIVATIVE COMPOUNDS, AND USES THEREOF | VORONOI INC. (KR) | 2024-01-25 | — | — | US | disclosed |
| WO-2023187471-A1 | HETEROARYL DERIVATIVE COMPOUNDS, AND USES THEREOF | VORONOI INC. (KR) | 2023-10-05 | — | — | WO | disclosed |
| US-10709692-B2 | Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1) | DENALI THERAPEUTICS INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20180353480-A1 | ISOXAZOLIDINE DERIVED INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE 1 (RIPK1) | APTUIT (VERONA) S.R.L. (IT) | 2018-12-13 | — | — | US | disclosed |
| WO-2017096301-A1 | ISOXAZOLIDINE DERIVED INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE 1 (RIPK 1) | DENALI THERAPEUTICS INC. (US) | 2017-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037330-B2 | Heteroaryl derivative compounds, and uses thereof | ERBB2, EGFR, ERBB3 | RIPK1 1316/4885HSD11B1 3354/4885CHRNB2 4459/4885 |
| US-20180353480-A1 | ISOXAZOLIDINE DERIVED INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE 1 (RIPK1) | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885HSD11B1 4404/4885CHRNB2 2282/4885 |
| US-10709692-B2 | Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1) | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885HSD11B1 4404/4885CHRNB2 2282/4885 |
| US-20240166640-A1 | HETEROARYL DERIVATIVE COMPOUNDS, AND USES THEREOF | ERBB2, EGFR, ERBB3 | RIPK1 1316/4885HSD11B1 3354/4885CHRNB2 4459/4885 |
| US-20240025888-A1 | HETEROARYL DERIVATIVE COMPOUNDS, AND USES THEREOF | ERBB2, EGFR, ERBB3 | RIPK1 1316/4885HSD11B1 3354/4885CHRNB2 4459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.